Statement: until a complete response is achieved, or the disease progresses, the intervention protocol of the primary clinical trial will persist.
Primary_evidence: INTERVENTION 1:    Pemetrexed   600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression